Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.18
Bid: 4.00
Ask: 4.32
Change: -0.39 (-8.57%)
Spread: 0.32 (8.00%)
Open: 4.32
High: 4.32
Low: 4.16
Prev. Close: 4.55
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Developments with Harpin

14 Nov 2018 07:00

RNS Number : 2566H
Plant Health Care PLC
14 November 2018
 

 

 

14 November 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Positive Developments with Harpin ab in sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on the launch of H2Copla (Harpin ab) in sugarcane in Brazil.

 

Highlights:

- H2Copla (Harpin ab) has been applied on some 20,000 hectares (Ha) of sugarcane since 'soft launch' in February 2018

- Average yield increases in excess of 20% are driving strong demand; early adopters plan to switch entirely to H2Copla for the next season

- Grower response to the results has been very positive

- Sales by PHC to Coplacana are expected to reach $0.8m in 2018, pointing to strong growth in 2019

 

As previously announced, Brazil sugarcane, with 10 million Ha planted, is an important target for Plant Health Care. The Company has been developing Harpin ab for use in this crop since 2016. Coplacana, a very large co-operative and the leading distributor of inputs for sugarcane, was appointed as distributor to launch Harpin ab under the brand name H2Copla. Following a 'soft launch' in February 2018, Coplacana has been carrying out extensive demonstration trials of the product; H2Copla has been applied on some 20,000 Ha to date by various growers.

 

Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha), significantly increased the yield of sugarcane (10-29%). Moreover, it is possible that the life of the crop may be extended from five to six years, resulting in a material cost reduction for the grower, especially when sugar prices are low. Grower response to the results has been very positive.

 

Furthermore Usina Açucareira Furlan S/A ('Furlan'), a large sugarcane producer located in the state of São Paulo, carried out field trials in 2018, as part of the soft launch by Coplacana, which delivered an average 23% yield increase from H2Copla applicatons. Furlan now plans to use H2Copla on their entire area next season.

 

Gilmar Rorigues de Morais, Agriculture Department Manager at Furlan, said "We are excited about the yield increases from this year's trials and plan to use H2Copla on all of our 20,000 Ha for the 2019 growing season."

 

Chris Richards, Executive Chairman and Interim CEO of Plant Health Care, noted: "Grower reaction to demonstration trials of H2Copla has been very positive. Growers have already treated some 20,000 Ha of sugarcane with the product. The indication that just one customer (Furlan) plans to use H2Copla on 20,000 Ha next year, points to significant revenue growth in 2019. Demand for Harpin ab in Brazil is expected to reach at least $0.8m in 2018."

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeff Tweedy, COO

 

Arden Partners plc - Nomad and BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUOUWRWSAAAAA
Date   Source Headline
8th May 20247:00 amRNSTrading Update
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.